Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now expands to six marketed products and several other assets in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.
Content supported by this sponsor
The sponsor did not influence the content provided here
Oncology in Practice
Management of drug-drug interactions with kinase inhibitors
A comprehensive resource that reviews the clinically relevant drug-drug interactions with kinase inhibitors, explores the mechanism of each type of interaction, and provides specific recommendations to guide physicians and clinical pharmacists in daily clinical practice
Management of skin toxicities from multikinase inhibitor therapies
Information, treatment algorithms and educational materials on the management of dermatological side effects associated with multikinase inhibitors, provided in two sections specifically tailored to healthcare professionals or patients and their caregivers
Targeting NTRK Gene Fusions
Two modules that offer comprehensive information on TRK fusion cancer, including an overview of how testing for NTRK gene fusions across multiple tumour types allows for the identification of patients who may benefit from TRK inhibitor therapy
Content donated by this sponsor
Industry-sponsored satellite symposia
TRK fusion lung cancer: A new precision oncology approach – European Lung Cancer Congress 2019
A Bayer-sponsored satellite symposium entitled ‘TRK fusion lung cancer: A new precision oncology approach’, was presented at the European Lung Cancer Congress 2019 in Geneva, Switzerland. Hear Professor Lukas Bubendorf and Dr Alexander Drilon explore the role of TRK fusion proteins as primary oncogenic drivers in TRK fusion lung cancer.
A selection of images and infographics that illustrate key concepts of tumour pathophysiology and management strategies, which you can download to enhance your presentations and educational sessions
Other initiatives supported by this sponsor
The sponsor did not influence the content of these initiatives
Expert video reports: Precision Medicine
A series of experts video reports provide you with the opportunity to learn about the most recent, exciting advancements in precision medicine directly from top-tier oncologists, including innovative therapeutic approaches, key clinical trial results, diagnostic strategies and epidemiological overviews
ESMO advanced courses
These include state of the art lectures, workshops and interactive discussion seminars, and are suitable for experienced oncologists and other specialists complementing the topics covered in the Preceptorship Programme. Each course is accredited with ESMO-MORA CME points (8–12)
ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.